Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
JINS HoldingsFRA:5F3 -19.61%97 Return-on-Tangible-Equity is 30.57% as of Feb. 2026, which is 63% above its 10-year median of 18.70. GuruFocus rates FRA:5F3 with a GF Score™ of 97/100 and a GF Value™ of €36.43. Among 760 Medical Devices & Instruments companies, JINS Holdings ranks better than 89.08% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. JINS Holdings's annualized net income for the quarter that ended in Feb. 2026 was €42.1 Mil. JINS Holdings's average shareholder tangible equity for the quarter that ended in Feb. 2026 was €137.8 Mil. Therefore, JINS Holdings's annualized Return-on-Tangible-Equity for the quarter that ended in Feb. 2026 was 30.57%.
The historical rank and industry rank for JINS Holdings's Return-on-Tangible-Equity or its related term are showing as below:
FRA:5F3'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 4.15 Med: 18.7 Max: 33.92
Current: 32.47
During the past 13 years, JINS Holdings's highest Return-on-Tangible-Equity was 33.92%. The lowest was 4.15%. And the median was 18.70%.
FRA:5F3's Return-on-Tangible-Equity is ranked better than 89.08% of 760
companies
in the Medical Devices & Instruments industry
Industry Median: 4.03
vs FRA:5F3: 32.47
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
JINS Holdings Return-on-Tangible-Equity Related Terms
JINS Holdings Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for JINS Holdings's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:5F3 vs ISRG, BDX, MDLN: Return-on-Tangible-Equity Comparison
For the Medical Instruments & Supplies subindustry, JINS Holdings's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
JINS Holdings Return-on-Tangible-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, JINS Holdings's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where JINS Holdings's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Feb. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 30.57% mean?
JINS Holdings (FRA:5F3) has a Return-on-Tangible-Equity of 30.57% as of Feb. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on JINS Holdings and its competitors. This is 63% above median its historical median of 18.70. Over the past decade, JINS Holdings' Return-on-Tangible-Equity has ranged from 4.15 to 33.92. According to the industry distribution chart, JINS Holdings ranks #83 out of 760 companies in the Medical Devices & Instruments industry, placing it in the top 10.9%.
Is JINS Holdings' Return-on-Tangible-Equity too high?
JINS Holdings' current Return-on-Tangible-Equity of 30.57% is 63% above median its 10-year median of 18.70. Over the past 10 years, this metric has ranged from a low of 4.15 to a high of 33.92. The Medical Devices & Instruments industry median Return-on-Tangible-Equity is 4.03. JINS Holdings' value of 30.57% is 658.6% above this industry median. Based on the distribution chart, JINS Holdings ranks #83 out of 760 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, JINS Holdings has a GF Score™ of 97/100, reflecting its overall financial health beyond just this single metric.
How does JINS Holdings' Return-on-Tangible-Equity compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, JINS Holdings ranks #83 out of 760 companies for Return-on-Tangible-Equity. This places JINS Holdings in the top 11% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 4.03. JINS Holdings' value of 30.57% is 658.6% above this benchmark. Historically, JINS Holdings' own Return-on-Tangible-Equity has ranged from 4.15 to 33.92 over the past decade. While the company's 10-year median is 18.70 vs. the industry median of 4.03, JINS Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.03, based on 760 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. JINS Holdings's current Return-on-Tangible-Equity of 30.57% is 658.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on JINS Holdings and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. JINS Holdings's current Return-on-Tangible-Equity is 30.57%, which is 63% above median its own 10-year median of 18.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is JINS Holdings stock overvalued right now?
JINS Holdings (FRA:5F3) has a current Return-on-Tangible-Equity of 30.57%. The stock's GF Value™ is €36.43, compared to a current price of €32.80 — trading 10% below its estimated fair value. The current Return-on-Tangible-Equity is 30.57%, which is 63% above median its 10-year median of 18.70 and 658.6% above the Medical Devices & Instruments industry median of 4.03. JINS Holdings' overall GF Score™ is 97/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For JINS Holdings (FRA:5F3), the current Return-on-Tangible-Equity is 30.57% as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is JINS Holdings (FRA:5F3) Overvalued in 2026?
Based on GuruFocus' analysis, JINS Holdings stock appears to be undervalued.
The current stock price of €32.80 is trading 10% below its estimated GF Value™ of €36.43.
Key valuation signals for FRA:5F3:
Return-on-Tangible-Equity: 30.57% (63% above median its 10-year median of 18.70)
GF Value™: €36.43 vs. price of €32.80 (10% below fair value)
Industry Position: 658.6% above the Medical Devices & Instruments median (#83 of 760)
No single metric tells the full story. See the FRA:5F3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
JINS Holdings Inc is an eyewear retailer that manufactures and sells private-label fashion eyeglasses and sunglasses. It offers prescription eyeglasses and nonprescription fashion or functional eyeglasses. Its inventory is on the shelves, and it charges flat rates with generally no additional charges or options for lens features. Jin has more than 300 stores in Japan as well as locations in China, Taiwan, and the United States. Stores are typically located in high-traffic areas such as shopping centers, malls, and train stations.
97GF Score
Get the complete analysis for FRA:5F3
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:5F3 has been successfully added to your 
